Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: A single centre experience

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 1, 2012, Pages 287-292

  Gigante, Antonietta ^a   Salviani, C ^a   Giannakakis, K ^a   Rosato, E ^a   Barbano, B ^a   Amoroso, A ^a   Gasperini, M L ^a   Nofroni, I ^a   Salsano, F ^a   Cianci, R ^a   Pugliese, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ANCA; Pauci immune crescentic necrotizing glomerulonephritis; Renal limited vasculitis; Vasculitis

Indexed keywords

CREATININE; COMPLEMENT COMPONENT C3C;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; ITALY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY NECROSIS; MALE; OUTCOME ASSESSMENT; PAUCI IMMUNE CRESCENTIC GLOMERULONEPHRITIS; PRIORITY JOURNAL; RENAL LIMITED VASCULITIS; SMALL VESSEL VASCULITIS; SURVIVAL; ARTERIOLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; GLOMERULAR FIBRINOID NECROSIS; HISTOLOGY; HUMAN TISSUE; KIDNEY ARTERY; MIDDLE AGED; PAUCI IMMUNE CRESCENTRIC GLOMERULONEPHRITIS; PREDICTIVE VALUE; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RETROSPECTIVE STUDY;

EID: 84861469910     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500133     Document Type: Article

References (22)

1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337(21):1512-23. (Pubitemid 27495778)
2. Mukhtyar C, Luqmani R. Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. Clin Exp Rheumatol 2007; 25 (S): 120-9.
3. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003; 63(3): 1164-77. (Pubitemid 36315601)
4. Jennette JC, Thomas DB. Crescentic glomerulonephritis. Nephrol Dial Transplant 2001; (S)6:80-2.
5. Jennette JC, Olson JL, Schwartz MM. Crescentic glomerulonephritis in Heptinstall's Pathology of the Kidney (5th ed), edited by Philadelphia, Lippincott-Raven 1998; 625-56.
6. Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, Lesavre P, Noël LH. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005; 20(7):1392-9. (Pubitemid 41430612)
7. Hauer HA, Bajema IM, van Houwelingen HC, et al: European Vasculitis Study Group (EUVAS). Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002; 61(1):80-9. (Pubitemid 34075133)
8. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010; 10(3):464-71.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2):S1-266.
10. De Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006; 17(8): 2264-74. (Pubitemid 44141917)
11. Holmén C, Christensson M, Pettersson E, Bratt J, Stjärne P, Karrar A, Sumitran-Holgersson S. Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies. Kidney Int 2004; 66(3): 1049-60. (Pubitemid 39121009)
12. Hoffman GS. Determinants of vessel targeting in vasculitis. Clin Dev Immunol 2004; 11(3-4):275-9. (Pubitemid 39423308)
13. Rutgers A, Sanders JS, Stegeman CA, Kallenberg CG: Pauci-immune necrotizing glomerulonephritis. Rheum Dis Clin North Am 2010; 36(3):559-72.
14. Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant 2005; 20(1):96-104. (Pubitemid 40207613)
15. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7(1):23-32. (Pubitemid 26067088)
16. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR; PanThames Renal Research Group. Outcome of ANCAassociated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41(4):776-84. (Pubitemid 36396745)
17. Fisher JW Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003; 228(1):1-14. (Pubitemid 36077622)
18. Chen M, Kallenberg CG, Zhao MH. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol 2009; 5(6):313-8.
19. Van Timmeren MM, Chen M, Heeringa P. Pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Nephrology (Carlton) 2009; 14(1):16-25.
20. Haas M, Eustace JA. Immune complex deposits in ANCA associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int 2004; 65:2145-52. (Pubitemid 38670000)
21. Chen M, Xing GQ, Yu F, Liu G, Zhao MH. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant 2009; 24(4): 1247-52.
22. Xing GQ, Chen M, Liu G, Heeringa P, Zhang JJ, Zheng X, E J, Kallenberg CG, Zhao MH. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009; 29(3):282-91.